A detailed history of New York State Common Retirement Fund transactions in Argenx Se stock. As of the latest transaction made, New York State Common Retirement Fund holds 104,534 shares of ARGX stock, worth $62.2 Million. This represents 0.08% of its overall portfolio holdings.

Number of Shares
104,534
Previous 119,983 12.88%
Holding current value
$62.2 Million
Previous $51.6 Million 9.82%
% of portfolio
0.08%
Previous 0.07%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 28, 2024

SELL
$434.22 - $551.9 $6.71 Million - $8.53 Million
-15,449 Reduced 12.88%
104,534 $56.7 Million
Q2 2024

Jul 31, 2024

SELL
$356.01 - $451.55 $1.25 Million - $1.59 Million
-3,514 Reduced 2.85%
119,983 $51.6 Million
Q1 2024

May 07, 2024

SELL
$356.95 - $413.29 $8.09 Million - $9.37 Million
-22,671 Reduced 15.51%
123,497 $48.6 Million
Q4 2023

Feb 01, 2024

BUY
$338.91 - $506.01 $6.45 Million - $9.63 Million
19,032 Added 14.97%
146,168 $55.6 Million
Q3 2023

Nov 07, 2023

SELL
$369.35 - $548.43 $2.84 Million - $4.22 Million
-7,694 Reduced 5.71%
127,136 $62.5 Million
Q2 2023

Aug 07, 2023

BUY
$360.14 - $422.58 $590,629 - $693,031
1,640 Added 1.23%
134,830 $52.5 Million
Q1 2023

May 02, 2023

BUY
$334.23 - $403.65 $5.1 Million - $6.15 Million
15,246 Added 12.93%
133,190 $49.6 Million
Q4 2022

Jan 30, 2023

SELL
$342.17 - $402.31 $796,229 - $936,175
-2,327 Reduced 1.93%
117,944 $44.7 Million
Q3 2022

Nov 08, 2022

SELL
$343.2 - $395.75 $1.61 Million - $1.85 Million
-4,682 Reduced 3.75%
120,271 $42.5 Million
Q2 2022

Aug 04, 2022

BUY
$269.58 - $378.88 $637,826 - $896,430
2,366 Added 1.93%
124,953 $47.3 Million
Q1 2022

May 05, 2022

BUY
$254.45 - $351.06 $4.82 Million - $6.64 Million
18,928 Added 18.26%
122,587 $38.7 Million
Q4 2021

Feb 02, 2022

SELL
$272.01 - $353.03 $5.53 Million - $7.17 Million
-20,318 Reduced 16.39%
103,659 $36.3 Million
Q3 2021

Nov 02, 2021

SELL
$295.0 - $350.58 $866,120 - $1.03 Million
-2,936 Reduced 2.31%
123,977 $37.4 Million
Q2 2021

Aug 02, 2021

BUY
$257.11 - $319.92 $107,214 - $133,406
417 Added 0.33%
126,913 $38.2 Million
Q1 2021

May 11, 2021

BUY
$268.3 - $380.31 $1.02 Million - $1.45 Million
3,810 Added 3.11%
126,496 $34.8 Million
Q4 2020

Feb 08, 2021

SELL
$248.13 - $308.36 $874,161 - $1.09 Million
-3,523 Reduced 2.79%
122,686 $36.1 Million
Q3 2020

Nov 05, 2020

SELL
$215.51 - $272.51 $172,408 - $218,008
-800 Reduced 0.63%
126,209 $33.1 Million
Q2 2020

Aug 07, 2020

BUY
$127.44 - $232.72 $483,252 - $882,474
3,792 Added 3.08%
127,009 $28.6 Million
Q1 2020

May 06, 2020

BUY
$108.83 - $165.23 $576,146 - $874,727
5,294 Added 4.49%
123,217 $16.2 Million
Q4 2019

Feb 05, 2020

BUY
$106.59 - $164.21 $2.85 Million - $4.38 Million
26,699 Added 29.27%
117,923 $18.9 Million
Q3 2019

Nov 07, 2019

BUY
$113.31 - $150.51 $954,070 - $1.27 Million
8,420 Added 10.17%
91,224 $10.4 Million
Q2 2019

Aug 09, 2019

BUY
$115.0 - $141.58 $453,100 - $557,825
3,940 Added 5.0%
82,804 $11.7 Million
Q1 2019

May 08, 2019

BUY
$98.85 - $134.59 $300,899 - $409,691
3,044 Added 4.01%
78,864 $9.85 Million
Q4 2018

Feb 08, 2019

BUY
$63.81 - $109.82 $1.15 Million - $1.99 Million
18,079 Added 31.31%
75,820 $7.28 Million
Q3 2018

Nov 07, 2018

BUY
$75.5 - $96.63 $3.63 Million - $4.65 Million
48,121 Added 500.22%
57,741 $4.38 Million
Q2 2018

Aug 10, 2018

BUY
$74.84 - $100.16 $235,746 - $315,504
3,150 Added 48.69%
9,620 $797,000
Q1 2018

May 10, 2018

SELL
$56.95 - $85.19 $148,582 - $222,260
-2,609 Reduced 28.74%
6,470 $520,000
Q4 2017

Feb 13, 2018

BUY
$22.57 - $63.56 $204,913 - $577,061
9,079 New
9,079 $573,000
Q3 2017

Nov 06, 2017

SELL
$19.81 - $22.61 $36,589 - $41,760
-1,847 Closed
0 $0
Q2 2017

Aug 11, 2017

BUY
N/A
1,847
1,847 $39,000

Others Institutions Holding ARGX

About ARGENX SE


  • Ticker ARGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,323,800
  • Market Cap $32.9B
  • Description
  • argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...
More about ARGX
Track This Portfolio

Track New York State Common Retirement Fund Portfolio

Follow New York State Common Retirement Fund and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of New York State Common Retirement Fund, based on Form 13F filings with the SEC.

News

Stay updated on New York State Common Retirement Fund with notifications on news.